Srx Health Solutions Inc (SRXH) Stock Analysis
Verdict: AVOID
Terminal cash burn and 95% revenue collapse make this a high-probability bankruptcy candidate despite speculative AI labeling.
Investment score: 18/100
Analysis as of
Is Srx Health Solutions Inc stock worth reviewing? The TradeMates thesis
The TradeMates model identifies SRXH as a distressed micro-cap with a broken balance sheet. With revenue plummeting 95% year-over-year and cash reserves insufficient to cover the next quarter's operations, the recent 'strategic' investment in Vistagen appears to be a desperate pivot. The 19.3x P/B ratio is a massive red flag compared to industry peers.
7-factor investment score
- Valuation: 5/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 5/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Srx Health Solutions Inc opportunities and risks
What speaks for SRXH
- Extreme Mean Reversion
What speaks against SRXH
- Imminent Liquidity Exhaustion
Peers and competitors
- MGRX
- BLMH
- HEWA
- NGMC
- HESG
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SRXH | n/a | n/a | n/a | 26.9% | 168.6% | -131.2% |
| MGRX | n/a | 20.1x | n/a | 52.4% | -4632.9% | -58.5% |
| BLMH | n/a | 0.2x | n/a | 43.9% | -62.2% | -79.7% |
| HEWA | n/a | 0.2x | 23.5x | 39.5% | -0.7% | -78.6% |
| NGMC | n/a | 0.2x | 18.7x | 31.9% | -2.4% | 0.0% |
| HESG | n/a | 5.2x | n/a | 7.0% | -15.2% | 2.2% |
| Peer median | n/a | 0.2x | n/a | 39.5% | -15.2% | -58.5% |
Frequently asked questions about Srx Health Solutions Inc (SRXH)
Is SRXH stock a good investment?
The TradeMates model rates Srx Health Solutions Inc as AVOID with an investment score of 18/100. The TradeMates model identifies SRXH as a distressed micro-cap with a broken balance sheet. With revenue plummeting 95% year-over-year and cash reserves insufficient to cover the next quarter's operations, the recent 'strategic' investment in Vistagen appears to be a desperate pivot. The 19.3x P/B ratio is a massive red flag compared to industry peers. This is algorithmic model output, not personal investment advice.
Is SRXH stock a buy?
The TradeMates model verdict for SRXH is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.